- cafead   Jun 24, 2019 at 07:32: PM
via Conatus Pharmaceuticals Inc said on Monday it plans to explore options and implement a restructuring plan after its liver disease drug failed in a mid-stage trial.
The drug developer's shares halved to 48 cents after the bell.
article source
The drug developer's shares halved to 48 cents after the bell.
article source